Fusion Pharmaceuticals Inc (FUSN) Key Ratios
$21.55
$0.00 (0.00%)As on 04-Jun-2024 16:00EDT
Market cap
$1,833 Mln
Revenue (TTM)
$36 Mln
P/E Ratio
--
P/B Ratio
8.1
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | 3,846.46 | 58.33 | -- |
| EBIT | -26.83 | -44.28 | -16.97 | -185.95 | -252.18 |
| Net Profit | -19.49 | -38.61 | -13.35 | -7.85 | -243.78 |
| EPS | 6.12 | 10.89 | 26.99 | 24.68 | -- |
| Book Value | -- | -- | -8.57 | -36.85 | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-23 | Dec-22 |
| EBIT-Margin
| -5,506.51 | -5,950.18 | -302.83 | -4,798.45 | -6,025.60 |
| Net Margin
| -5,249.72 | -3,430.28 | -292.29 | -- | -5,868.18 |
| Return on equity
| -41.55 | -24.34 | -48.47 | -49.34 | -44.51 |
| Return on Capital
| -36.71 | -19.59 | -- | -39.93 | -39.76 |
| Return on Assets
| -34.52 | -35.38 | -33.19 | -37.59 | -37.18 |
| Debt to Equity (x)
| -- | -- | 0.21 | 0.23 | 0.25 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Fusion Pharmaceuticals Inc (FUSN)
|
--
|
-39.93
|
-39.76
|
-30.43
|
-58.73
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-48.47
Lower than Peers by 32.49
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Fusion Pharmaceuticals Inc (FUSN)
|
-48.47
|
-49.34
|
-44.51
|
-30.82
|
-60.02
|
|
Peer Median
|
-15.98
|
--
|
--
|
--
|
--
|
ROA
-33.19
Lower than Peers by 21.33
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Fusion Pharmaceuticals Inc (FUSN)
|
-33.19
|
-37.59
|
-37.18
|
-28.79
|
-41.22
|
|
Peer Median
|
-11.85
|
--
|
--
|
--
|
--
|
EBIT Margin
-302.83
Lower than Peers by 275.77
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Fusion Pharmaceuticals Inc (FUSN)
|
-302.83
|
-4,798.45
|
-6,025.60
|
-5,695.49
|
-7,281.19
|
|
Peer Median
|
-27.06
|
--
|
--
|
--
|
--
|
Net Margin
-292.29
Lower than Peers by 259.60
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Fusion Pharmaceuticals Inc (FUSN)
|
-292.29
|
-4,588.83
|
-5,868.18
|
-4,631.26
|
208.62
|
|
Peer Median
|
-32.69
|
--
|
--
|
--
|
--
|
Cash Profit Margin
0.00
Lower than Peers by 0.00
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Fusion Pharmaceuticals Inc (FUSN)
|
0.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.00
|
--
|
--
|
--
|
--
|
Revenue Growth
3,846.46
Higher than Peers by 3,812.49
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Fusion Pharmaceuticals Inc (FUSN)
|
3,846.46
|
0.42
|
0.01
|
1.76
|
--
|
|
Peer Median
|
33.97
|
--
|
--
|
--
|
--
|
EBIT Growth
-16.97
Higher than Peers by 8.29
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Fusion Pharmaceuticals Inc (FUSN)
|
-16.97
|
-12.72
|
-7.34
|
-116.20
|
-108.21
|
|
Peer Median
|
-25.26
|
--
|
--
|
--
|
--
|
Net Profit Growth
-13.35
Higher than Peers by 8.23
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Fusion Pharmaceuticals Inc (FUSN)
|
-13.35
|
-8.32
|
-8.10
|
-3.46
|
-383.87
|
|
Peer Median
|
-21.58
|
--
|
--
|
--
|
--
|
EPS Growth
26.99
Higher than Peers by 33.16
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Fusion Pharmaceuticals Inc (FUSN)
|
26.99
|
0.28
|
-0.06
|
0.47
|
0.56
|
|
Peer Median
|
-6.17
|
--
|
--
|
--
|
--
|
Book Value Growth
-22.59
Lower than Peers by 19.70
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Fusion Pharmaceuticals Inc (FUSN)
|
-22.59
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-2.89
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.21
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Fusion Pharmaceuticals Inc (FUSN)
|
0.21
|
0.23
|
0.25
|
0.03
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.02
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Fusion Pharmaceuticals Inc (FUSN)
|
0.02
|
0.02
|
0.01
|
0.01
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
10.64
Higher than Peers by 1.53
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Fusion Pharmaceuticals Inc (FUSN)
|
10.64
|
15.01
|
11.88
|
16.93
|
19.24
|
|
Peer Median
|
9.11
|
--
|
--
|
--
|
--
|
Quick Ratio
10.64
Higher than Peers by 1.53
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Fusion Pharmaceuticals Inc (FUSN)
|
10.64
|
--
|
12.54
|
16.10
|
18.89
|
|
Peer Median
|
9.11
|
--
|
--
|
--
|
--
|
Interest Coverage
-16.90
Lower than Peers by 17.62
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Fusion Pharmaceuticals Inc (FUSN)
|
-16.90
|
-19.21
|
-48.88
|
-96.49
|
-116.01
|
|
Peer Median
|
0.72
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
13.12
Lower than Peers by 9.64
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Fusion Pharmaceuticals Inc (FUSN)
|
13.12
|
203.82
|
117.93
|
24.79
|
152.40
|
|
Peer Median
|
22.75
|
--
|
--
|
--
|
--
|
Asset Turnover
0.11
Higher than Peers by 0.06
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Fusion Pharmaceuticals Inc (FUSN)
|
0.11
|
0.01
|
0.01
|
0.01
|
0.00
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Fusion Pharmaceuticals Inc (FUSN)
|
--
|
524.38
|
260.00
|
145.97
|
428.35
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Fusion Pharmaceuticals Inc (FUSN)
|
--
|
-2,680.04
|
1.58
|
47.38
|
1,798.59
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Fusion Pharmaceuticals Inc (FUSN)
|
--
|
617.26
|
15.14
|
18.13
|
1,602.33
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Fusion Pharmaceuticals Inc (FUSN)
|
--
|
-2,772.91
|
246.44
|
175.23
|
624.61
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Fusion Pharmaceuticals Inc (FUSN)
|
--
|
-6.68
|
-1.58
|
-2.21
|
-3.30
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
8.13
Higher than Peers by 3.43
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Fusion Pharmaceuticals Inc (FUSN)
|
8.13
|
2.85
|
0.85
|
0.77
|
0.88
|
|
Peer Median
|
4.69
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Fusion Pharmaceuticals Inc (FUSN)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-18.55
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Fusion Pharmaceuticals Inc (FUSN)
|
-18.55
|
-4.60
|
-0.09
|
0.18
|
-1.16
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
1,833
Higher than Peers by 1,619
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Fusion Pharmaceuticals Inc (FUSN)
|
1,833
|
--
|
--
|
--
|
--
|
|
Peer Median
|
214
|
--
|
--
|
--
|
--
|